Private Equity Moving Outside Surgical Specialties

2024-01-22T11:00:38+00:00Blogs, Healthcare|

In many ways, the third wave of private equity investment in physician-owned businesses is starting to mature. We view this third wave as having started around 2015 with investments in ophthalmology and dermatology practices. Earlier investments in radiology and emergency medicine, or pure-play ASCs, are really part of an earlier wave.

White Paper: Private Equity Investment in Physician Owned Specialty Practices

2024-01-22T11:00:29+00:00Downloads, Healthcare, White Papers|

The FOCUS healthcare team represents medical practices and ancillary businesses in specialties where private equity-backed consolidation is occurring. We track activity in key verticals and maintain strong relationships with private equity firms and their portfolio companies.

FOCUS Investment Banking Represents Clinart in its Acquisition by Greater Cincinnati-based CTI Clinical Trial and Consulting Services

2024-02-12T23:33:19+00:00Healthcare, Life Sciences, Mergers & Acquisitions News, Mergers, Acquisitions & Divestitures|

FOCUS Investment Banking (“FOCUS”), a Washington DC-based investment bank, represented Clinart, a regional CRO (Contract Research Organization) located in Dubai, in its acquisition by CTI, Clinical Trial and Consulting Services, an international CRO headquartered in Cincinnati, Ohio.

White Paper: Private Equity Investment in Ophthalmology – August 2020 State of the Market

2024-01-22T11:00:20+00:00Downloads, Healthcare, White Papers|

A comprehensive view of ophthalmology's recovery from the pandemic shutdown. We review changes in elective surgery, the emerging investor interest in retina practices, private  equity acquisition activity, geographic development, and changes to acquisition practice size. As the COVID-19 fog begins to clear, we see significant near-term promise and a potential return to record deal levels.

White Paper: Private Equity Investment in Dermatology – April 2020 State of the Market

2024-01-22T11:00:22+00:00Downloads, Healthcare, White Papers|

After seven strong years, private equity investment in dermatology has been in decline since 2019. Now, elective procedure bans and shelter-in-place orders have practice owners wondering if the opportunity to sell has passed. This paper  examines  the differing views on pe-backed consolidation, key performance indicators, investor activity, and saturation by geography and practice size. We see several positive factors for our current and potential clients within a coming private equity player restructuring.

Go to Top